Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: BG Medicine, Caprotec, and More

Premium

BG Medicine has appointed Charles Abdalian to be executive VP and chief financial officer. Mike Rogers will be departing the company after three-and-a-half years as CFO.

Abdalian most recently was VP and CFO at Knome, and he has been CEO at Pelias Technologies and CFO at Molecular Insight Pharmaceutical Group and Emisphere Technologies.


Caprotec Bioanalytics has appointed Jonathan Turner to be CEO and managing director. Turner will take over the CEO spot from company founder Hubert Koester, who will continue to work with the company as acting chief scientific officer and chairman of the scientific advisory board.

Turner formerly was senior vice president at XL Techgroup, a technology developer and equity firm, and he held senior management posts at Boehringer Ingelheim, AstraZeneca, and Schering.


Aushon Biosystems this week appointed Bill Williams vice president of sales.

Williams was previously founder and owner of the life sciences market research firm Web Prospects. Before that he was US national sales manager for Ciphergen Biosystems.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.